Key facts
- GS Biotech’s last known valuation is $417.3M (Feb 2025).
- It has raised $56.2M; the latest was Early Stage VC ($27.6M) in Feb 2025.
- Notable investors include Plug and Play Tech Center, Puhua Capital, Legend Capital, 5Y Capital, Eastern Bell Venture Capital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for GS Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for GS Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GS Biotech
Developer of furans bio-based materials designed to reduce carbon emissions. The company engages in biomass catalytic conversion and furan-based material design and development, contributing to the carbon peak and carbon neutrality targets.
- Sector
- Materials and Resources
- HQ
- Hangzhou, China
- Founded
- 2021
- Website
- guoshengtech.com/
- Ownership
- Privately Held (backing)
GS Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GS Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GS Biotech in its N-PORT filings yet. We sweep new filings monthly.